Industrial conglomerate 3M has demonstrated accelerating progress in its business turnaround, according to recent financial results and strategic updates. The company has worked through a period of significant litigation challenges, including settlements exceeding $10 billion related to water contamination claims involving PFAS chemicals and additional payments to veterans regarding defective earplugs. Management indicated the company is moving beyond this phase as stakeholders redirect attention toward growth prospects and profitability improvements.
Operational enhancements have been a key driver of the company’s momentum. Chief Executive William Brown reported that on-time, in-full delivery rates have risen from the low 80% range to approximately 90%, with certain consumer business units consistently surpassing 90%. The company has also accelerated its innovation pipeline, with more than 350 product launches planned. New products are anticipated to comprise 20% of sales by the end of 2027, and management cited expanded beam optical technology as a significant opportunity in data center applications, expecting approximately $400 million in growth above underlying market rates.
Financial performance in the second quarter reflected these improvements, with adjusted net sales reaching $6.50 billion, representing 5.5% year-over-year growth. Adjusted operating income increased 7.2% year-over-year to $1.62 billion, while adjusted earnings per share climbed 11.1% to $2.40. The company subsequently raised its full-year targets, increasing organic sales growth guidance from approximately 3% to more than 3.5% and revising earnings per share expectations to a range of $8.80 to $8.95, reflecting growth of 9% to 11%.
Wall Street sentiment has remained mixed regarding the turnaround narrative. Mizuho maintained a neutral stance while raising its price target from $160 to $180. Bernstein SocGen raised its target to $145 but kept an underperform rating, expressing caution about confirming structural improvement and noting concerns about PFAS as a lingering risk. UBS provided more optimistic commentary, raising its price target to $218 while maintaining a buy rating. The consensus rating across 16 analysts is moderate buy, with a price target of $187.81 representing 15.5% upside potential from then-current levels.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI